Apnimed Announces Pricing of Upsized Initial Public Offering
Key Highlights
- ➤Apnimed (APMD) priced upsized IPO of 12M shares at $16.00 per share.
- ➤Underwriters have 30-day option to buy additional 1.8M common shares.
- ➤Gross proceeds to Apnimed (APMD) expected $192M, excluding underwriter option exercise.
- ➤Apnimed (APMD) common stock expects to trade on Nasdaq Global Select Market July 31, 2026.
- ➤Offering expected to close around August 3, 2026, subject to closing conditions.
- ➤BofA Securities, Evercore ISI, Cantor, LifeSci Capital are joint book-running managers.
- ➤Apnimed (APMD) NDA for AD109 has PDUFA goal date of February 28, 2027.
CAMBRIDGE, Mass., July 30, 2026 /PRNewswire/ -- Apnimed, Inc. ("Apnimed"), a late stage clinical pharmaceutical company dedicated to the discovery, development, and commercialization of novel oral therapies that address the neurobiology of sleep-related breathing diseases, today announced the pricing of its upsized initial public offering of 12,000,000 shares of its common stock at a price to the public of $16.00 per share. In addition, Apnimed has granted the underwriters a 30-day option to buy an additional 1,800,000 shares of its common stock at the initial public offering price, less underwriting discounts and commissions.
Apnimed common stock is expected to begin trading on the Nasdaq Global Select Market on July 31, 2026, under the ticker symbol "APMD". The offering is expected to close on or about August 3, 2026, subject to the satisfaction of customary closing conditions.
Get started
Create a free account to read the full story.